Cytomed Therapeutics refutes ‘misleading’ claims, reaffirms clinical progress

6 days ago 13

TipRanks

Thu, January 29, 2026 astatine 9:11 AM CST 2 min read

CytoMed Therapeutics (GDTC) issued a connection to code caller statements containing “inaccurate and misleading” claims regarding the Company’s probe programs, objective progress, and operations.The institution said, ” CytoMed categorically rejects specified claims which person nary basis. Certain statements circulating publically mis-characterize the Company’s technological focus, improvement status, and regulatory standing. Please notation to caller announcements by the Company connected our progress. CytoMed’s probe is focused connected CAR gammadelta T compartment therapies and iPSC-derived gammadelta NKT compartment therapies, based connected established immunological science. The Company’s pb CAR gammadelta T compartment programme has received regulatory support to proceed with a first-in-human objective trial, which is presently ongoing astatine National University Hospital, Singapore. This objective enactment is conducted successful accordance with applicable regulatory and ethical requirements. Other programs, including iPSC-derived gammadelta NKT compartment candidates, stay successful preclinical development. CytoMed does not assertion that immoderate of its therapeutic candidates are approved for commercialized usage oregon clinically validated beyond their existent signifier of development. Assertions regarding CytoMed’s regulatory status, manufacturing capabilities, governance, oregon fiscal transparency that contradict the supra facts are inaccurate oregon taken retired of discourse and designed to impact the Company’s stock price. The Company operates successful compliance with applicable regulations and follows improvement practices due for its stage. CytoMed remains committed to advancing its pipeline responsibly and to communicating accurate, timely accusation done authoritative Company disclosures. The Company reserves the close to instrumentality due enactment to code the dissemination of mendacious oregon misleading accusation that whitethorn adversely impact its estimation oregon stakeholders.”

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See Insiders’ Hot Stocks connected TipRanks >>

Read More connected GDTC:

Disclaimer & DisclosureReport an Issue

CytoMed Therapeutics Outlines 2026 Clinical Plans and Seeks Shareholder Input connected Patient-Access Scheme
Cytomed sees ‘enough resources’ to proceed activites for ‘at slightest a year’
CytoMed Therapeutics Partners with Malaysian Hospital for Groundbreaking Cancer Trial
Cytomed Therapeutics enters into MoU with UMMC

Read Entire Article